Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore‐Bianchi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Salvatore Siena(University of Milan)
Cited by 257
Related Papers
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
|Annals of Oncology|2019|300
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
|Nature Medicine|2022|251
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent <i>In vivo</i> Activity in Mesothelioma
|Clinical Cancer Research|2007|93
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
|Cancer Immunology Research|2022|73